<DOC>
	<DOCNO>NCT01335698</DOCNO>
	<brief_summary>The purpose study describe safety , efficacy , pharmacokinetics regimen atazanavir powder boost ritonavir optimized dual nucleoside reverse transcriptase inhibitor pediatric patient age ≥3 month &lt; 11 year .</brief_summary>
	<brief_title>Phase IIIB Study Evaluating Effects Atazanavir Powder With Ritonavir HIV-infected Pediatric Patients</brief_title>
	<detailed_description />
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Key Confirmed HIV1 infection diagnose protocol criterion Screening HIV RNA level ≥1000 copies/mL ≥3 month &lt; 11 year age time first treatment Antiretroviralnaive experience At screening , participant must genotypic sensitivity atazanavir least 2 nucleoside reverse transcriptase inhibitor ( NRTIs ) , must approve pediatric use local country . Antiretroviralexperienced patient must also document phenotypic sensitivity screen atazanavir ( Fold Change susceptibility &lt; 2.2 ) least 2 NRTIs approve country Key Experienced participant receive atazanavir atazanavir/ritonavir time prior study enrollment history 2 protease inhibitor failures Antiretroviralnaïve experience HIV1infected patient contraindication study medication Cardiac rhythm abnormality Need tenofovir Weight &lt; 5 ≥35kg &gt; Grade 2 abnormality aspartate transaminase/alanine transaminase level Coinfection either hepatitis B C virus Any active Centers Disease Control Prevention Category C clinical condition</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Pediatric</keyword>
</DOC>